• BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, previously listed as NasdaqGM:FOLD.
• Following the transaction, Amicus has been delisted from the Nasdaq and removed from major indices including the S&P and Russell families.
• The deal ends Amicus's status as an independent public company and sets up integration of its rare disease portfolio into BioMarin.

For investors who followed Amicus Therapeutics at a share price of $14.49 and a value score of 3, the completed acquisition caps a period of strong long term returns, including 88.7% over 1 year and 51.1% over 5 years. With NasdaqGM:FOLD no longer trading, the focus shifts from day to day market moves to what the transaction means for the products and programs now moving under the BioMarin umbrella.

This change also matters for anyone tracking biotech indices or using index funds in this space, as Amicus is now removed from major benchmarks such as the S&P and Russell indices. Investors may want to review how the removal of Amicus and the addition of any replacement constituents could affect sector exposure and portfolio concentration in the future.

Stay updated on the most important news stories for Amicus Therapeutics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Amicus Therapeutics.

Quick Assessment

• ⚖️ Price vs Analyst Target: The current price of US$14.49 is almost identical to the analyst target of US$14.50, so there is little implied upside or downside from the deal pricing.
• ⚖️ Simply Wall St Valuation: Shares are described as trading close to estimated fair value, so the acquisition price broadly aligns with intrinsic value estimates.
• ✅ Recent Momentum: A 30 day return of 0.42% suggests the stock price has been relatively stable into the completion of the transaction.

There is only one way to know the right time to buy, sell or hold Amicus Therapeutics. Head to Simply Wall St's company report for the latest analysis of Amicus Therapeutics's Fair Value.

Key Considerations

• 📊 With Amicus now part of BioMarin and removed from indices, your exposure becomes indirect through any BioMarin or broader healthcare holdings.
• 📊 Pay attention to how BioMarin reports on integration progress, rare disease revenue contribution and any updated guidance tied to the acquired portfolio.
• ⚠️ Index fund investors may see small shifts in sector weights as Amicus exits benchmarks and replacements are added, which can slightly change portfolio risk profiles.

Dig Deeper

For the full picture, including more risks and rewards, check out the complete Amicus Therapeutics analysis. Alternatively, you can visit the community page for Amicus Therapeutics to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.